15 December 2017 Meeting Minutes
A teleconference/Skype for Business meeting was held on 15 December 2017. The group discussed further the advantages and uses of HistoGraphic, using the eTOX data as an example. A very useful feature is the ability to search by organ or lesion/finding, using key words, which will display results across multiple studies. Important aspect for effective use of the tool is controlled terminology so that data can be aggregated in a consistent fashion. This is a key aspect of the SEND initiative. K Snyder is piloting use of HistoGraphic at FDA, and providing demonstrations to other Pharm/Tox Reviewers. A draft abstract for a poster for the 2018 FDA PhUSE CSS was prepared by A Brown and shared with the group. The group endorsed the abstract for submission. The poster will provide an introduction into the software, which was developed to display various types of hierarchical data (originally for metagenomic data), followed by screen shot images depicting the various hierarchies of the data and results of search terms (lesions for example, necrosis, depletion, etc). This working group was the first to utilize the software and make adaptations for histopathology data from toxicology studies. The group reviewed the license information for the software (Krona). Our group is free to operate and is not in violation of the license. The eTOX consortium will evaluate whether HistoGraphic can be utilized with the eTOX database. eTRANSAFE will have a data visualization component and P Drew will inquire how this working group can interact with eTRANSAFE. S Troth has been involved with a Society of Toxicologic Pathology working group on data visualization and a publication on the use of various tools for displaying clinical and anatomic pathology will be submitted in 2018. Sean can share contents of the paper at a future meeting. J Zandee had eTOX data entered into SEND Explorer software and will share results at a future meeting. Working group needs to determine future goals and objectives for 2018. Possibilities include interactions with eTRANSAFE, exploring visualization of clinical data as guides for nonclinical.